Key Facts

Invested since 2022

About the company

smartbax is developing a new generation of antibiotics to address the increasing spread of multidrug-resistant bacteria. Their team of experts works on innovative solutions focusing on substances that simultaneously address several targets, thus hindering resistance development in bacteria. Moreover, the company specializes in the tailored activation of enzymatic pathways, as this approach is particularly promising in the context of difficult-to-treat biofilms. Knowing that preventing a resistance crisis tomorrow means taking action today, smartbax was founded in 2021 in Munich with the aim of making innovative research applicable in creating novel antibiotics that add true value for patients worldwide.

Do you want to

know more about this company?

Zum Artikel

Dr. Angelika Vlachou Partner

Dr. Angelika VlachouPartner

smartbax in the news

Zum Artikel

News

23. May 2023

smartbax Announces Seed Financing of €1.2 Million to Develop Next-generation Antibiotics

More startups from Life Sciences